Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01448-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Roberto Sánchez-Sánchez und 13 weiteren Autor:innen. Beteiligte Einrichtung: SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of M…. Hauptthemen laut MEDLINE: Toxoplasma, Toxoplasmosis, Animal, Sheep Diseases, Toxoplasmosis, Congenital. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, U.S. Department of Agriculture (USDA), Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF).
Abstract (Originalsprache)
Drug development for congenital toxoplasmosis is challenging since first-line therapy has a high rate of adverse effects and exhibits suboptimal efficacy. Bumped kinase inhibitors (BKIs), targeting protein kinases with small gatekeeper residues, have been found to be effective against Toxoplasma gondii . The efficacy of BKI-1748 administered later than 2 days post-infection (p.i.), a scenario that may better reflect its real-world use as a therapeutic candidate, has not been investigated in T. gondii -infected pregnant sheep. For this purpose, 19 pregnant sheep were assigned to three experimental groups. Group 1 (G1, n = 8) and group 2 (G2, n = 8) were dosed orally with 10 TgShSp1 sporulated oocysts at 90 days of gestation (dg). Animals from group 3 (G3, n = 3) were simultaneously mock dosed with phosphate-buffered solution (PBS). In G1, BKI-1748 was administered orally from day 7 p.i. (fever and increased serum IFNγ levels) onward, maintaining drug exposure for 20 days (10 doses at 15 mg/kg every 2 days). Treated animals (G1) exhibited significantly lower rectal temperatures (on days 8 and 9 p.i.), serum IFNγ levels (on day 10 p.i.), and specific IgG levels when compared with non-treated animals (G2). At delivery, significantly higher percentages of healthy lambs were found in infected/treated sheep in G1 (73.3%) and in uninfected sheep in G3 (80%) compared with infected/untreated sheep in G2 (31.3%). Concerning congenital transmission, parasite DNA was neither detected in placenta nor target tissues (brain and lungs) from the fetuses/lambs in G1(infected/treated) and G3 (uninfected). By contrast, parasite DNA was detected in all placentas and lambs from G2 (infected/untreated), except for one sheep that aborted on day 13 p.i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
- Animal Health Department, University of Murcia, Murcia, Region of Murcia, Spain.
- SALUVET-Innova S.L., Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy.
- Animal Medicine and Surgery Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
- Center for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Roberto Sánchez-Sánchez, Matthew A Hulverson, Samuel L M Arnold, Luis Miguel Ortega-Mora
Förderung
- NICHD NIH HHS
- U.S. Department of Agriculture (USDA)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Sánchez-Sánchez, R., Huertas-López, A., Largo-de la Torre, A., Ferre, I., Dini, F. M., Re, M., Moreno-Gonzalo, J., Choi, R., Hulverson, M. A., Ojo, K. K., Arnold, S. L. M., Hemphill, A., Van Voorhis, W. C., & Ortega-Mora, L. M. (2025). Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01448-24
Vancouver
Sánchez-Sánchez R, Huertas-López A, Largo-de la Torre A, Ferre I, Dini FM, Re M, et al. Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01448-24
BibTeX
@article{SnchezSnchez2025,
author = {Sánchez-Sánchez, Roberto and Huertas-López, Ana and Largo-de la Torre, Andrea and Ferre, Ignacio and Dini, Filippo Maria and Re, Michela and Moreno-Gonzalo, Javier and Choi, Ryan and Hulverson, Matthew A and Ojo, Kayode K and Arnold, Samuel L M and Hemphill, Andrew and Van Voorhis, Wesley C and Ortega-Mora, Luis Miguel},
title = {Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01448-24}
}
EUVIMED